Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-46
Empagliflozin
Cat. No.
AKA-46
CAS No.
864070-44-0
MF
C23H27ClO7
MW
450.9
Empagliflozin is a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com
Technical Data
Description
Storage and Shipping
References
Product Name
Empagliflozin
CAS No.
864070-44-0
MF
C23H27ClO7
MW
450.9
Specification
99%
Description
Empagliflozin is a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor. Packing: 1kg/bag; 25kg/drum or as request Availability: In Stock
Documents
Certificate of Analysis (COA), API specification, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes, Obesity & Metabolism. 2012 Jan;14(1):83-90. PMID: 21985634
[2]. Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PloS One. 2016 Jan 25;11(1):e0147391. PMID: 26807719
[3]. Byrne NJ, et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC. Basic to Translational Science. 2017 Aug;2(4):347-354.
[4]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. International Journal of Medical Sciences. 2018 Jun 13;15(9):937-943. PMID: 30008607
[2]. Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PloS One. 2016 Jan 25;11(1):e0147391. PMID: 26807719
[3]. Byrne NJ, et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC. Basic to Translational Science. 2017 Aug;2(4):347-354.
[4]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. International Journal of Medical Sciences. 2018 Jun 13;15(9):937-943. PMID: 30008607
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
AKA-384
Tedizolid phosphate
CAS No.: 856867-55-5
MF:C17H16FN6O6P
AKA-383
Brivaracetam
CAS No.:357336-20-0
MF:C11H20N2O2
AKA-382
Cobimetinib Fumarate
CAS No.:1369665-02-0
MF:C46H46F6I2N6O8
AKA-379
Bempedoic acid
CAS No.:738606-46-7
MF:C19H36O5
AKA-378
Borofalan(10B)
CAS No.:80994-59-8
MF:C9H12BNO4
AKA-377
AkProva™ Metildigoxin
CAS No.:30685-43-9(acetone-free)
MF:C42H66O14.1/2C3H6O
AKA-376
AkProva™ beta-Acetyldigoxin
CAS No.:5355-48-6
MF:C43H66O15
AKA-375
Ak-NucleoVia™ Agrostemmoside E
CAS No.:2656438-29-6
MF:C84H128O45
AKA-374
Novobiocin sodium
CAS No.:1476-53-5
MF:C31H35N2NAO11
AKA-360
Travoprost
CAS No.:157283-68-6
MF:C26H35F3O6
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
